These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11741696)

  • 1. Quantity and quality of virus-specific CD8 cell response: relevance to the design of a therapeutic vaccine for chronic HBV infection.
    Webster G; Bertoletti A
    Mol Immunol; 2001 Dec; 38(6):467-73. PubMed ID: 11741696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
    Reynolds TD; Buonocore L; Rose NF; Rose JK; Robek MD
    J Virol; 2015 Oct; 89(20):10407-15. PubMed ID: 26246574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.
    Moshkani S; Chiale C; Lang SM; Rose JK; Robek MD
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic vaccination against chronic hepatitis B virus infection.
    Michel ML; Mancini-Bourgine M
    J Clin Virol; 2005 Dec; 34 Suppl 1():S108-14. PubMed ID: 16461209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards immunotherapy for chronic hepatitis B virus infections.
    Michel ML
    Vaccine; 2002 Dec; 20 Suppl 4():A83-8. PubMed ID: 12477434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
    Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
    Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic vaccination against chronic hepatitis B virus infection].
    Mancini-Bourgine M; Michel ML
    Therapie; 2005; 60(3):257-65. PubMed ID: 16128268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
    Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
    J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection.
    Kosinska AD; Moeed A; Kallin N; Festag J; Su J; Steiger K; Michel ML; Protzer U; Knolle PA
    Sci Rep; 2019 Jul; 9(1):10808. PubMed ID: 31346211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing an immunodominant epitope of hepatitis B surface antigen reveals an alternative repertoire of CD8 T cell epitopes of this viral antigen.
    Wieland A; Riedl P; Reimann J; Schirmbeck R
    Vaccine; 2009 Dec; 28(1):114-9. PubMed ID: 19818719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel T-cell epitope in the transmembrane region of the hepatitis B virus envelope protein responds upon dendritic cell expansion.
    Chen L; Zhang Y; Zhang S; Chen Y; Shu X; Lai J; Cao H; Lian Y; Stamataki Z; Huang Y
    Arch Virol; 2019 Feb; 164(2):483-495. PubMed ID: 30415392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic polypeptides based on HBcAg(18-27) CTL epitope can induce antigen-specific CD(8)(+) CTL-mediated cytotoxicity in HLA-A2 transgenic mice.
    Shi TD; Wu YZ; Jia ZC; Zhou W; Zou LY
    World J Gastroenterol; 2004 Apr; 10(8):1222-6. PubMed ID: 15069731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections.
    Kakimi K; Isogawa M; Chung J; Sette A; Chisari FV
    J Virol; 2002 Sep; 76(17):8609-20. PubMed ID: 12163580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide vaccines against hepatitis B virus: from animal model to human studies.
    Engler OB; Dai WJ; Sette A; Hunziker IP; Reichen J; Pichler WJ; Cerny A
    Mol Immunol; 2001 Dec; 38(6):457-65. PubMed ID: 11741695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An immunodominant HLA-A*1101-restricted CD8+ T-cell response targeting hepatitis B surface antigen in chronic hepatitis B patients.
    Chen X; Wang W; Wang S; Meng G; Zhang M; Ni B; Wu Y; Wang L
    J Gen Virol; 2013 Dec; 94(Pt 12):2717-2723. PubMed ID: 23997182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of TLR2-ligand-synthetic long peptide conjugates for therapeutic vaccination of chronic HBV patients.
    Dou Y; Jansen DTSL; van den Bosch A; de Man RA; van Montfoort N; Araman C; van Kasteren SI; Zom GG; Krebber WJ; Melief CJM; Woltman AM; Buschow SI
    Antiviral Res; 2020 Jun; 178():104746. PubMed ID: 32081741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8
    Zhang Y; Wu Y; Deng M; Xu D; Li X; Xu Z; Hu J; Zhang H; Liu K; Zhao Y; Gao F; Bi S; Gao GF; Zhao J; Liu WJ; Meng S
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.
    Boni C; Janssen HLA; Rossi M; Yoon SK; Vecchi A; Barili V; Yoshida EM; Trinh H; Rodell TC; Laccabue D; Alfieri A; Brillo F; Fisicaro P; Acerbi G; Pedrazzi G; Andreone P; Cursaro C; Margotti M; Santoro R; Piazzolla V; Brunetto MR; Coco B; Cavallone D; Zhao Y; Joshi A; Woo J; Lau AH; Gaggar A; Subramanian GM; Massetto B; Fung S; Ahn SH; Ma X; Mangia A; Ferrari C
    Gastroenterology; 2019 Jul; 157(1):227-241.e7. PubMed ID: 30930022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell therapy for chronic viral hepatitis.
    Bertoletti A; Tan AT; Koh S
    Cytotherapy; 2017 Nov; 19(11):1317-1324. PubMed ID: 28847469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B virus splice-generated protein induces T-cell responses in HLA-transgenic mice and hepatitis B virus-infected patients.
    Mancini-Bourgine M; Bayard F; Soussan P; Deng Q; Lone YC; Kremsdorf D; Michel ML
    J Virol; 2007 May; 81(10):4963-72. PubMed ID: 17360751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.